Fosfenopril Attenuates Inflammatory Response in Diabetic Dry Eye Models by Inhibiting the TLR4/NF-κB/NLRP3 Signaling Pathway

PURPOSE. The purpose of this study was to investigate the involvement of the TLR4/NF-KB/NLRP3 signaling pathway and its underlying mechanism in diabetic dry eye. METHODS. Two models of diabetic dry eye were established in high glucose-induced human corneal epithelial (HCE-T) cells and streptozotocin (STZ)-induced C57BL/6 mice, and the TLR4 inhibitor fosfenopril (FOS) was utilized to suppress the TLR4/NF-KB/NLRP3 signaling pathway. The expression changes in TLR4, NF-KB, NLRP3, and IL-1/3, and other factors were detected by Western blot and RT-qPCR, the wound healing rate was evaluated by cell scratch assay, and the symptoms of diabetic mice were evaluated by corneal sodium fluorescein staining and tear secretion assay. RESULTS. In the diabetic dry eye model, the transcript levels of TLR4, NF-KB, NLRP3, and IL-1/3 were raised, and further application of FOS, a TLR4 inhibitor, downregulated the levels of these pathway factors. In addition, FOS was found to be effective in increasing the wound healing rate of high glucose-induced HCE-T cells, increasing tear production, and decreasing corneal fluorescence staining scores in diabetic mice, as measured by cell scratch assay, corneal sodium fluorescein staining assay, and tear production. CONCLUSIONS. The current study found that the TLR4/NF-KB/NLRP3 signaling pathway regulates diabetic dry eye in an in vitro and in vivo model, and that FOS reduces the signs of dry eye in diabetic mice, providing a new treatment option for diabetic dry eye.